GlobalData on MSN9h
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBVThe trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.
Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback